Ahead of the 2026 ASCO Annual Meeting, several trial updates released with pre-meeting abstracts spotlight both clinical and health-economic endpoints across gastrointestinal and genitourinary oncology. Coverage includes cost-utility results from CHALLENGE in resected colon cancer and perioperative data in urothelial carcinoma from KEYNOTE-B15/EV-304, alongside CHRYSALIS-2 for atypical EGFR-mutant NSCLC.